{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-008268","form_type":"8-K","ticker":"KAPA","cik":"0001962011","company_name":"Kairos Pharma, LTD.","filed_at":"2025-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.663025+00:00","generated_at":"2026-05-26T04:00:41.695016+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"medium","headline":"Kairos Pharma presents preclinical data for KROS 101 and KROS 401 at AACR IO","bullets":["KROS 101 (GITR agonist) inhibited tumor growth in melanoma model and increased CD4+/CD8+ T cell proliferation.","KROS 101 prevented T cell exhaustion, a key advantage over prior GITR antibody TRX518.","KROS 401 peptide inhibitor reduced M2 macrophages and showed anti-tumor effect in glioma-bearing mice.","Data presented at AACR Immuno-Oncology conference in Los Angeles, February 23-26, 2025.","CEO highlighted potential of KROS platform to address T cell exhaustion and reprogram tumor microenvironment."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-008268","json":"https://secwatch.observer/filing/0001493152-25-008268.json","markdown":"https://secwatch.observer/filing/0001493152-25-008268.md","text":"https://secwatch.observer/filing/0001493152-25-008268.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1962011/000149315225008268/0001493152-25-008268-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1962011/000149315225008268/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T04:00:41.695016+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}